Register Login

Marinus Pharmaceuticals Inc (MRNS)

  • Event
  • June 08, 2022, 11:34 UTC

(10% Negative) Marinus Pharmaceuticals, Inc. (MRNS) Announces Delay in proposal Trials for a potential interim analysis Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 5:20 a.m.

    📋 Marinus Pharmaceuticals, Inc. (MRNS) - Clinical Trial Update

    Filing Date: 2022-06-08

    Accepted: 2022-06-08 07:34:42

    Event Type: Clinical Trial Update

    Event Details:

    Marinus Pharmaceuticals Inc (MRNS) Announces Clinical Trial Update Marinus Pharmaceuticals Inc (MRNS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: proposal, treated
    • Diseases/Conditions: a potential interim analysis
    • Clinical Stage: Phase 3, Phase 2
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: RSE
      • targeting 10 new sites and is evaluating further expansion into Israel and Australia. The company is targeting 65-75 sites globally and continues to expect topline data in the second half of 2023

    🔬 Clinical Development Pipeline (Marinus Pharmaceuticals, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Ganaxolone DRUG Phase PHASE3 Tuberous Sclerosis Complex ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Marinus Pharmaceuticals Inc
    • CIK: 0001267813
    • Ticker Symbol: MRNS
    • Period End Date: 2022-06-08
    • Document Type: 8-K

Search

News categories